New guidelines out on drug purchasing
Two researchers have published new guidelines for managed care systems to evaluate drug products.
Two researchers have published new guidelines for managed care systems to evaluate drug products.
The guidelines, which are the first published in the United States, are aimed at giving purchasers and drug manufacturers direction on what types of economic and clinical analysis are most useful when determining which drugs to include on formulary.
Paul Langley, Ph.D., associate professor with the Center for Pharmaceutical Economics at the University of Arizona's College of Pharmacy, Tucson, and Sean Sullivan, Ph.D., assistant professor with the Department of Pharmacy and Health Services at the University of Washington, Seattle, wrote the template. The guidelines appear in the Nov./Dec. issue of the Journal of Managed Care Pharmacy, the journal of the Academy of Managed Care Pharmacy, Alexandria, VA.
The guidelines stress the need for drug manufacturers to provide pharmacoeconomic and other data designed to show how a particular drug will affect a specific patient population within a defined health care system.
The guidelines suggest that manufacturers provide cost assessments for the first three years the product is on formulary. "To assess the cost impact, proposers must estimate and justify the rate of uptake of the new therapy, characteristics of the treating population (including comorbidities), patterns of substitution for other products and resources used to support therapy," the guidelines state. "Cost estimates should include the cost of treating adverse events."
One large health maintenance organization, Foundation Health Plan, Rancho Cordova, CA, is adopting drug evaluation guidelines based largely on Langley and Sullivan's work. PR
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Study: GLP-1, SGLT2s Linked to Reduced Alzheimer Disease Risk in Patients with Type 2 Diabetes
April 17th 2025A new study found that patients with type 2 diabetes treated with GLP-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors demonstrated lower risks of developing Alzheimer disease compared to other glucose-lowering drugs.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
New Insights Into T Cell Exhaustion and Inflammation in Long COVID
April 17th 2025Nigel McCracken, chief operating officer, Virax Biolabs, discusses new findings that reveal altered cytokine activity and evidence of T cell exhaustion in long COVID patients, providing deeper insight into post-infection immune disruption.
